Fig. 2
From: Economic evaluation of COVID-19 rapid antigen screening programs in the workplace
Projected average daily incidence of all (symptomatic and asymptomatic) infections for TOSC (black); SP1 in workplaces without a confirmatory test (blue); SP2 in workplaces with a confirmatory RT-PCR test (orange); and SP3 in workplaces with a confirmatory RA test (red). Screening programs were implemented for 50% of workplaces with a size of 50+ employees. The booster vaccination among adults aged 18–64 years was set to reported coverage as of April 1, 2022 [status quo] (A1–A5); an increase of 20% over status quo (B1–B5); and an increase of 80% over status quo (C1–C5). Shaded areas indicate the duration of SP1, SP2, and SP3; testing of severe cases with RT-PCR tests was implemented throughout the entire simulation. For SP2, RA-positive cases were isolated while awaiting the RT-PCR test result